

SAFETY DATA SHEETS

This SDS packet was issued with item:

078071062

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078074096 078305912

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078074070 078074088

Orbax[®] (EX000030)

This product is exempt from [Material] Safety Data Sheet requirements.

The following regional exemptions apply:

United States:

According to the OSHA Hazard Communication Standard [29 CFR § 1910.1200 (b) (6) (vii)], an MSDS is not required for any drug when it is in the solid, final form (*e.g.* tablets or pills).

European Union:

According to the European Union Commission Directive 2001/58/EC of 27 July 2001, as it relates to Directive 1999/45/EC [Article 1.5.a], an SDS is not required for medicinal products in the finished state, intended for the final user.

Canada:

According to the WHMIS Hazardous Product Act [Part II Controlled Products 12.b], an MSDS is not required for any drug within the meaning of the *Food and Drugs Act*.

If you have additional MSDS requests, please call the Schering-Plough MSDS Help Line at 800-770-8878 (U.S. and Canada) or 908-473-3371 (worldwide) or Schering-Plough marketed products may be also obtained at www.schering-ploughmsds.com. Email MSDS requests to spmsds@spcorp.com.

For inquiries for any of the following; call the designated numbers below:

- Adverse Event
- Product Complaint
- Product Quality Complaint

Designated points of contact in the United States are as follows:

Prescription Pharmaceutical (Rx)	Animal Health (AH) Products	Consumer Health Care Products
Phone: 800-526-4099 Fax: 973-921-7006	Companion Animal/Aquaculture Phone: 800-224-5318 Livestock – Phone: 800-211-3573 Poultry – Phone: 800-219-9286	Phone: 800-842-4090 Fax: 901-320-2292

Thank you for your cooperation.

Sincerely,
Global Safety & Environmental Affairs
Schering-Plough Corporation

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

SECTION 1. IDENTIFICATION

Product name : Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Reproductive toxicity : Category 2

Specific target organ
systemic toxicity - repeated
exposure (Oral) : Category 2 (Eyes)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Eyes) through prolonged
or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
and understood.
P260 Do not breathe mist or vapors.
P280 Wear protective gloves/ protective clothing/ eye protection/
face protection.

Response:

Orbifloxacin Liquid Formulation

Version 3.0 Revision Date: 10/20/2017 SDS Number: 785439-00005 Date of last issue: 05/02/2017
Date of first issue: 06/28/2016

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Propylene glycol	57-55-6	$\geq 10 - < 20$
Orbifloxacin	113617-63-3	$\geq 1 - < 5$
Silicon dioxide	7631-86-9	$\geq 1 - < 5$
Lactic acid	50-21-5	$\geq 1 - < 3$
Sodium hydroxide	1310-73-2	$\geq 1 - < 2$

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.

Orbifloxacin Liquid Formulation

Version 3.0 Revision Date: 10/20/2017 SDS Number: 785439-00005 Date of last issue: 05/02/2017
 Date of first issue: 06/28/2016

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid inhalation of vapor or mist.
 Do not swallow.
 Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Propylene glycol	57-55-6	TWA	10 mg/m ³	US WEEL
Orbifloxacin	113617-63-3	TWA	600 µg/m ³ (OEB 2)	Merck
Silicon dioxide	7631-86-9	TWA (Dust)	20 Million particles per cubic foot (Silica)	OSHA Z-3
		TWA (Dust)	80 mg/m ³ / %SiO ₂ (Silica)	OSHA Z-3
		TWA	6 mg/m ³ (Silica)	NIOSH REL
Sodium hydroxide	1310-73-2	C	2 mg/m ³	ACGIH
		C	2 mg/m ³	NIOSH REL
		TWA	2 mg/m ³	OSHA Z-1

Orbifloxacin Liquid Formulation

Version 3.0 Revision Date: 10/20/2017 SDS Number: 785439-00005 Date of last issue: 05/02/2017
Date of first issue: 06/28/2016

Hazardous components without workplace control parameters

Ingredients	CAS-No.
Lactic acid	50-21-5

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Color	:	light brown
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	--

Ingredients:**Propylene glycol:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rabbit): > 159 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Orbifloxacin:

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Dog): > 600 mg/kg Symptoms: Vomiting
---------------------	---	---

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Silicon dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Lactic acid:

Acute oral toxicity : LD50 (Rat): 3,543 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 7.94 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Product:

Species: Rabbit

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Result: No skin irritation

Ingredients:**Propylene glycol:**

Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Orbifloxacin:

Species: Rabbit
Method: Draize Test
Result: No skin irritation

Silicon dioxide:

Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Lactic acid:

Species: Rabbit
Result: Skin irritation

Sodium hydroxide:

Result: Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

Product:

Species: Rabbit
Result: Mild eye irritation

Ingredients:**Propylene glycol:**

Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405

Orbifloxacin:

Species: Rabbit
Result: Mild eye irritation
Method: Draize Test

Silicon dioxide:

Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

II**Lactic acid:**

Species: Chicken eye
Result: Irreversible effects on the eye

Sodium hydroxide:

Result: Irreversible effects on the eye

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Product:

Test Type: Magnusson-Kligman-Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Ingredients:**Propylene glycol:**

Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Orbifloxacin:

Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Lactic acid:

Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Sodium hydroxide:

Test Type: Human repeat insult patch test (HRIPT)
Routes of exposure: Skin contact
Result: negative

Germ cell mutagenicity

Not classified based on available information.

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Ingredients:**Propylene glycol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

Orbifloxacin:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: positive Test Type: Mouse Lymphoma Result: positive Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Silicon dioxide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Lactic acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Carcinogenicity

Not classified based on available information.

Ingredients:**Propylene glycol:**

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Orbifloxacin:

Species: Rat
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

Silicon dioxide:

Species: Rat
Application Route: Ingestion
Exposure time: 103 weeks
Result: negative

Lactic acid:

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Ingredients:**Propylene glycol:**

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Effects on fertility : Test Type: Three-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Ingestion
Result: negative

Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight
Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development., Skeletal malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Silicon dioxide:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Eyes) through prolonged or repeated exposure if swallowed.

Product:

Target Organs: Eyes

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Product:**

Species: Dog

NOAEL: 22.5 mg/kg

LOAEL: 37.5 mg/kg

Application Route: Oral

Exposure time: 30 Days

Symptoms: Gastrointestinal disturbance

Species: Dog

LOAEL: 75 mg/kg

Application Route: Oral

Exposure time: 10 Days

Symptoms: Salivation, Gastrointestinal disturbance, Vomiting

Species: Cat

LOAEL: 45 mg/kg

Application Route: Oral

Exposure time: 30 Days

Target Organs: Eyes

Symptoms: Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

Ingredients:**Propylene glycol:**

Species: Rat, male

NOAEL: 1,700 mg/kg

Application Route: Ingestion

Exposure time: 2 y

Orbifloxacin:

Species: Rat

NOAEL: 20 mg/kg

LOAEL: 80 mg/kg

Application Route: Oral

Exposure time: 3 Months

Target Organs: Testes, Liver, Kidney, spleen

Species: Mouse

NOAEL: 80 mg/kg

LOAEL: 250 mg/kg

Application Route: Oral

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance

Species: Juvenile dog
NOAEL: 2 mg/kg
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 90 Days
Target Organs: Bone
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Remarks: No significant adverse effects were reported

Species: Cat
NOAEL: 7.5 mg/kg
LOAEL: 22.5 mg/kg
Application Route: Oral
Exposure time: 1 Months
Symptoms: Gastrointestinal disturbance

Silicon dioxide:

Species: Rat
NOAEL: 1.3 mg/m³
Application Route: inhalation (dust/mist/fume)
Exposure time: 13 Weeks

Lactic acid:

Species: Rat
LOAEL: 886 mg/kg
Application Route: Skin contact
Exposure time: 13 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Ingredients:****Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

Remarks: May cause photosensitization.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Ingredients:**Propylene glycol:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l Exposure time: 48 h
Toxicity to algae	:	ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l Exposure time: 7 d
Toxicity to microorganisms	:	NOEC (Pseudomonas putida): > 20,000 mg/l Exposure time: 18 h

Silicon dioxide:

Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 10,000 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 1,000 mg/l Exposure time: 24 h Method: OECD Test Guideline 202
Toxicity to algae	:	EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
		NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials

Lactic acid:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 130 mg/l Exposure time: 96 h
Toxicity to daphnia and other	:	EC50 (Daphnia magna (Water flea)): 130 mg/l

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

aquatic invertebrates	Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 2.8 g/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50: > 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Persistence and degradability**Ingredients:****Propylene glycol:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 98.3 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---

Lactic acid:

Biodegradability	: Result: rapidly degradable
------------------	------------------------------

Bioaccumulative potential**Ingredients:****Propylene glycol:**

Partition coefficient: n-octanol/water	: log Pow: -1.07
--	------------------

Lactic acid:

Partition coefficient: n-octanol/water	: log Pow: -0.62
--	------------------

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

Ingredients	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Sodium hydroxide	1310-73-2	1000	100000

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Water	7732-18-5
Malt Extract	8002-48-0
2-Propenoic acid, 2-methyl-, polymer with methyl 2-methyl-2-propenoate	25086-15-1
Propylene glycol	57-55-6
Orbifloxacin	113617-63-3
Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

California List of Hazardous Substances


Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

California Permissible Exposure Limits for Chemical Contaminants

Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION**Further information****NFPA:****HMIS® IV:**

HEALTH	*	2
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
US WEEL	:	USA. Workplace Environmental Exposure Levels (WEEL)
ACGIH / C	:	Ceiling limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / C	:	Ceiling value not be exceeded at any time.
OSHA Z-1 / TWA	:	8-hour time weighted average

Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

OSHA Z-3 / TWA : 8-hour time weighted average
US WEEL / TWA : 8-hr TWA

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/20/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/02/2017
3.0	10/20/2017	785439-00005	Date of first issue: 06/28/2016

US / Z8